Evidence map›Paper›PMID 35705254›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

Type I IFN Signaling Is Essential for Preventing IFN-γ Hyperproduction and Subsequent Deterioration of Antibacterial Immunity during Postinfluenza Pneumococcal Infection.

Sunil Palani, Shruti Bansal, Atul K Verma, Christopher Bauer, Shengjun Shao, Md Bashir Uddin, Keer Sun

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sunil PalaniDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; and.ORCID 0000-0002-3990-0343
Shruti BansalDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Atul K VermaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; and.
Christopher BauerDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0002-5652-9582
Shengjun ShaoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; and.
Md Bashir UddinDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; and.ORCID 0000-0002-0045-9669
Keer SunDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; and kesun@utmb.edu.
The University of Texas Medical Branch at Galveston · USUniversity of Nebraska Medical Center · US

Funding

Oxidative Burst in Influenza and MRSA Co-infectionR01HL118408 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SUN, KEER · 2013 to 2022
$3.9M
SOCS1 regulations of influenza infectionR21AI128527 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SUN, KEER · 2018 to 2019
$419k
NHLBI NIH HHS R01 HL118408NIAID NIH HHS R21 AI128527
6 · The paper itself

Abstract

Postinfluenza bacterial pneumonia is a significant cause of hospitalization and death in humans. The mechanisms underlying this viral and bacterial synergy remain incompletely understood. Recent evidence indicates that influenza-induced IFNs, particularly type I IFN (IFN-I) and IFN-γ, suppress antibacterial defenses. In this study, we have investigated the relative importance and interplay of IFN-I and IFN-γ pathways in influenza-induced susceptibility to

Indexed as

CoinfectionInfluenza, HumanOrthomyxoviridae InfectionsPneumococcal InfectionsPneumonia, PneumococcalAnimalsAnti-Bacterial AgentsHumansInterferon-gammaInterferon Type IMiceMice, Inbred C57BLMice, KnockoutAnti-Bacterial AgentsInterferon-gammaInterferon Type I

Identifiers

PMID35705254
PMCPMC9247018
OpenAlexW4283025926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.